TITLE

Role of pharmacoeconomic analysis in R&D decision making: when, where, how?

AUTHOR(S)
Miller, Paul
PUB. DATE
January 2005
SOURCE
PharmacoEconomics;2005, Vol. 23 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Pharmacoeconomics is vitally important to drug manufacturers in terms of communicating to external decision-makers (payers, prescribers, patients) the value of their products, achieving regulatory and reimbursement approval and contributing to commercial success. Since development of new drugs is long, costly and risky, and decisions must be made how to allocate considerable research and development (R&D) resources, pharmacoeconomics also has an essential role informing internal decision-making (within a company) during drug development. The use of pharmacoeconomics in early development phases is likely to enhance the efficiency of R&D resource use and also provide a solid foundation for communicating product value to external decision-makers further downstream, increasing the likelihood of regulatory (reimbursement) approval and commercial success. This paper puts the case for use of pharmacoeconomic analyses earlier in the development process and outlines five techniques (clinical trial simulation [CTS], option pricing [OP], investment appraisal [IA], threshold analysis [TA] and value of information [VOI] analysis) that can provide useful input into the design of clinical development programmes, portfolio management and optimal pricing strategy. CTS can estimate efficacy and tolerability profiles before clinical data are available. OP can show the value of different clinical programme designs, sequencing of studies and stop decisions. IA can compare expected net present value (NPV) of different product profiles or study designs. TA can be used to understand development drug profile requirements given partial data. VOI can assist risk management by quantifying uncertainty and assessing the economic viability of gathering further information on the development drug. No amount of pharmacoeconomic data can make a bad drug good; what it can do is enhance the drug developers understanding of the characteristics of that drug. Decision-making, in light of this information, is likely to be better than that without it, whether it leads to faster termination of uneconomic projects or the allocation of more appropriate resources to attractive projects.
ACCESSION #
15969691

 

Related Articles

  • DICHOTOMOUS CHOICES ON LIFE-DILEMMA PROBLEMS, SUBJECTIVE EXPECTED UTILITY, AND THE GROUP SHIFT EFFECT. Jacoby, Marsha B. // Social Behavior & Personality: An International Journal;1975, Vol. 3 Issue 1, p71 

    Focuses on the results of the study establishing the respondent's perception towards risk-taking and caution in life-dilemma problems. Experiment conditions of questionnaires; Failure of the exercise to establish a generalization of the group shift research to real life groups making decisions...

  • Toward a Contingency Model of Strategic Risk Taking. Baird, Inga Skromme; Thomas, Howard // Academy of Management Review;Apr1985, Vol. 10 Issue 2, p230 

    A model of strategic risk taking incorporating environmental, industrial, organizational, decision maker, and problem variables is presented. The model is intended to be both a preliminary conceptualization of strategic risk taking and a stimulant for future research on risk taking in strategic...

  • Groupthink Reconsidered. Whyte, Glen // Academy of Management Review;Jan1989, Vol. 14 Issue 1, p40 

    History and the daily newspaper provide examples of policy decisions made by groups that resulted in fiascoes. The making of such decisions is frequently attributed to the group think phenomenon. A different perspective on the occurrence of policy fiascoes, prospect polarization, is offered....

  • UNEARTH THE HUMAN ELEMENT. Bloom, Larry J. // Smart Business Atlanta;Sep2012, Vol. 9 Issue 10, p8 

    In this article the author focuses on the need of managing cultural risk in a company. He states that solving problems and making decision both should be based on significant and accurate information otherwise it can result in faulty decisions. He also states that decisions should not be drawn...

  • FRAMING EFFECTS IN GROUP INVESTMENT DECISION MAKING: ROLE OF GROUP POLARIZATION. Pi-Yueh Cheng; Wen-Bin Chiou // Psychological Reports;Feb2008, Vol. 102 Issue 1, p283 

    Prospect theory proposes that framing effects result in a preference for risk-averse choices in gain situations and risk-seeking choices in loss situations. However, in group polarization situations, groups show a pronounced tendency to shift toward more extreme positions than those they...

  • A Fuzzy Group Decision Making Approach to Construction Project Risk Management. Nasirzadeh, F.; Maleki, H.; Khanzadi, M.; Mianabadi, H. // International Journal of Industrial Engineering & Production Res;Mar2013, Vol. 24 Issue 1, p71 

    Implementation of the risk management concepts into construction practice may enhance the performance of project by taking appropriate response actions against identified risks. This research proposes a multi-criteria group decision making approach for the evaluation of different alternative...

  • The Analytic Hierarchy Process at Dar Al-Hekma, Saudi Arabia. Bahurmoz, Asma M.A. // Interfaces;Jul/Aug2003, Vol. 33 Issue 4, p70 

    I designed and implemented a multicriteria group-decision-making model based on the analytic hierarchy process to select the best candidates to send overseas to do graduate studies and eventually become teachers at the newly created Dar Al-Hekma women's college in Jeddah, Saudi Arabia. Thus,...

  • The decision hedgehog for creative decision making. Humphreys, Patrick; Jones, Garrick // Information Systems & e-Business Management;Apr2008, Vol. 6 Issue 2, p117 

    This article introduces a fundamental evolution of the group decision support model from the single “decision-spine” which focuses on a single proceduralized context, to provide comprehensive Group Communication and Decision Support (GDACS). We show how GDACS can support creative...

  • Medicare patient being observed?  // Hospital Access Management;Sep2012, Vol. 31 Issue 9, p106 

    The article reports that hospitals are facing unsustainable position due to changes in policy by the Centers for Medicare and Medicaid Services (CMS) that are causing hospitals to place patients in observation status for more than 48 hours instead of admitting them. Hospitals face loss of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics